Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis acquires marketing rights to Xyzal

This article was originally published in The Tan Sheet

Executive Summary

Sanofi-Aventis assumes the U.S. marketing rights to UCB's prescription allergy drug Xyzal (levocetirizine dihydrochloride), which could be a future switch candidate. Belgium-based UCB licensed the marketing rights to Sanofi as part of an accelerated plan to transition its U.S. business to a purely specialty-focused biopharmaceutical company, UCB announced Jan. 29. The firm says it will exit the primary care market March 1. However, UCB will continue to receive a percentage of Xyzal profits, according to the release. The deal comes weeks after Sanofi acquired U.S.-based Chattem with the intention of using the company to switch its prescription allergy drug Allegra (1"The Tan Sheet" Jan. 4, 2010). The French firm may have plans for Xyzal to follow a similar potential switch path. Xyzal's patent exclusivity expires in 2013 and the drug is the follow-on to cetirizine - the active ingredient in McNeil Consumer Healthcare's OTC allergy drug Zyrtec. Sanofi is expanding its OTC business through acquisitions, mergers and joint ventures, like its partnership with Minsheng Pharmaceutical Group in China (see story p. 6)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS103762

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel